# A. Agent and version

- **Student / team:** Mei Qiong Xue / individual assignment
- **Assignment / specialist:** Assignment 6 / Emerging Technology Adoption Agent v1.1
- **Date:** Analysis 2026-11-06; GitHub record updated 2026-11-09
- **GitHub repository:** https://github.com/meix719/emerging-technology-agents
- **Branch:** assignment-6-adoption
- **Tested implementation commit:** e7345da9d7c4d4711e746cbeee26ea3e82d7b634
- **Frozen scaffold version:** MASY1800_ET_Agent_Scaffold_v1_0; integrity check passed

# B. Specialist purpose and context

- **Governing question:** Which adoption posture is appropriate for this organization, application and time?
- **Emerging technology:** Surgeon-controlled Mako robotic-arm assistance
- **Intended application:** Primary elective total knee replacement for advanced symptomatic osteoarthritis
- **Organization / industry:** Hypothetical teaching hospital A and community hospital B, England/NHS healthcare
- **Adoption posture:** A: research-oriented fast follower. B: conservative, with concrete resource constraints.
- **Risk / consequence context:** Patient harm is not reversible; a cancellable pilot does not remove clinical risk.
- **Decision / horizon:** Current adoption posture; 12-month planning horizon, review within 90 days

# C. Three-level finding

- **ET generally:** Clinical use is established, but superior recovery is not established consistently.
- **ET for this application:** Measure return to walking and daily activities against conventional total knee replacement.
- **ET in this organization:** A can plan controlled learning under capability assumptions; B has capability gaps requiring deferral.
- **Bounded implication:** A: conditional bounded experiment planning only. B: defer patient use.
- **Confidence / uncertainty:** Moderate posture confidence; uncertain local benefit, safety applicability, cost and unverified readiness.
- **Reconsideration trigger:** Relevant comparative evidence, verified safety/readiness, meaningful recovery gain and justified incremental cost

# D. Evidence and testing

- **Most important evidence:** S1-S2: NICE HTG743. S3-S4: RACER-Knee and trial team. S5: contrary early-benefit ROSA study. Full dated register is in the agent folder.
- **Primary test result:** Conditional bounded experiment; no permission to enrol patients before clinical gates close.
- **Contrast - stable:** The general technology evidence and intended application remain identical.
- **Contrast - changed:** B defers due to training, support and measurement constraints.
- **Additional stress test:** Aggressive A also defers when training and safety review are missing.
- **Weakness found:** Actual pre-build conversation used vague evidence/comparability conditions; see preserved v0 output.
- **Revision:** Define comparable evidence, label assumptions, require safety gates and direct recovery outcomes.
- **Remaining limitation:** Three same-conversation tests do not establish reliability. Trial correction and real readiness remain unresolved.

# E. Independent judgment and handoff

- **Credible for team consideration?:** Yes as a bounded, reviewable prototype; not clinically validated or ready to authorize patient use.
- **Recommendation to team:** Retain safety gates and conditional recommendations. If conditions cannot be represented downstream, use DEFER for immediate patient launch.
- **Organizational Adoption Agent handoff:** Verify training, operational ownership, service support, rehabilitation capacity and implementation workflow.
- **AI / verification note:** ChatGPT authored/tests the specialist using retrieved original-source materials; course validators, full JSON Schema checks and frozen-core integrity passed. Uploaded to GitHub on 2026-11-09. The implementation commit above preserves the tested agent; a subsequent documentation commit adds this completed record and reports.
